Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure
R.J. Kelly, A. Hill, L.M. Arnold, G. Khursigara, N.S. Kanagasundaram, P. Hillmen
20110301
2011 Apr 1
Leuk Res
Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure
Leuk Res. 2011 Apr;35(4):560-562, R.J. Kelly, A. Hill, L.M. Arnold, G. Khursigara, N.S. Kanagasundaram, P. Hillmen
1IntroductionParoxysmal nocturnal hemoglobinuria (PNH) is an acquired disease occurring due to a somatic mutation in hemopoietic stem cells resulting in reduced expression or absence of glycophosphatidylinositol (GPI) anchored proteins on blood cells including the GPI-linked complement inhibitors CD55 and CD59. As a result, PNH erythrocytes have an increased susceptibility to complement mediated lysis which leads to chronic hemolysis. Eculizumab is a humanized monoclonal antibody that specifically...
